All In Biotech

Drug Trial Radar · NCT02132767

Rate Control Versus Rhythm Control For Postoperative Atrial Fibrillation

Last checked: Nov 19, 2026Latest source record: Mar 15, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 523 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

523

Actual

Start

May 2014

Primary completion

Sep 2015

Study completion Sep 2015

Sponsor

Lead sponsor
Icahn School of Medicine at Mount SinaiAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Heart, Lung, and Blood Institute (NHLBI); National Institute of Neurological Disorders and Stroke (NINDS); Canadian Institutes of Health Research (CIHR)
First posted
May 7, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the therapeutic strategies of rate control versus rhythm control in cardiac surgery patients who develop in-hospital postoperative atrial fibrillation or atrial flutter (AF). In patients who develop AF during hospitalization after cardiac surgery, the hypothesis is that a strategy of rhythm control will reduce days in hospital within 60 days of the occurrence of AF compared to a strategy of rate control.

Conditions

  • Postoperative Atrial Fibrillation

Interventions

  • AmiodaroneDrug

    Amiodarone Initial Dose * Oral: 400 mg po TID for 3 days is recommended * For patients incapable of taking oral: 150 mg IV bolus over 10 min, then 1 mg/min over 6 hours followed by 0.5 mg/min over 18 hours Maintenance Dose * Oral: at least 200 mg/day to be continued until 60 days after randomization * If drug cannot be given orally or via NG tube: 0.5 mg/min administered through central line (e.g., PICC) until oral dosing is started

  • DC-cardioversionProcedure

    DC-Cardioversion - frequency and duration determined by medical professional as medically needed

  • Rate ControlDrug

    Beta-blocker and/or Calcium channel blockers and/or Digoxin - Dose, frequency and duration determined by medical professional as medically needed

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Total Number of Days in HospitalTime frame: Within 60 days of randomization

Locations

23 sites in 2 countries. Site status is shown where the registry gives one.

  • University of Southern California

    Los Angeles, California

  • Emory University

    Atlanta, Georgia

  • University of Maryland

    Baltimore, Maryland

  • NIH Heart Center at Suburban Hospital

    Bethesda, Maryland

  • University of Michigan Health Services

    Ann Arbor, Michigan

  • Icahn School of Medicine at Mount Sinai

    New York, New York

  • Columbia University Medical Center

    New York, New York

  • Montefiore Einstein Heart Center

    The Bronx, New York

  • Mission Hospital

    Asheville, North Carolina

  • Duke University

    Durham, North Carolina

  • Cleveland Clinic Foundation

    Cleveland, Ohio

  • The Ohio State University Medical Center

    Columbus, Ohio

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • Baylor College of Medicine

    Houston, Texas

  • Baylor Research Institute

    Plano, Texas

  • University of Virginia Health Systems

    Charlottesville, Virginia

  • University of Wisconsin

    Madison, Wisconsin

  • University of Alberta Hospital

    Edmonton, Alberta, Canada

  • Toronto General Hospital

    Toronto, Ontario, Canada

  • Montreal Heart Institute

    Montreal, Quebec, Canada

  • Centre Hospitalier de l'Université de Montréal

    Montreal, Quebec, Canada

  • Hôpital du Sacré-Cœur de Montréal

    Montreal, Quebec, Canada

  • Institut Universitaire de Cardiologie de Quebec (Hopital Laval)

    Québec, Quebec, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.